Role of the progesterone receptor (PR) in the regulation of inflammatory response pathways and aromatase in the breast

Journal of Steroid Biochemistry and Molecular Biology

Volumn 102, Issue 1-5 SPEC. ISS., 2006, Pages 241-249

  Mendelson, Carole R ^a   Hardy, Daniel B ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

Aromatase; Breast cancer; Cyclooxygenase 2; Inflammation; Nuclear factor B; Progesterone receptor

Indexed keywords

ANIMALS; AROMATASE; AROMATASE INHIBITORS; BREAST; CYCLOOXYGENASE 2; CYTOKINES; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MEMBRANE PROTEINS; NF-KAPPA B; RECEPTOR, ERBB-2; RECEPTORS, PROGESTERONE; SIGNAL TRANSDUCTION;

EID: 33750970565     PISSN: 09600760     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jsbmb.2006.09.029     Document Type: Article

References (86)

1. Brodie A.M., Lu Q., Long B.J., Fulton A., Chen T., Macpherson N., DeJong P.C., Blankenstein M.A., Nortier J.W., Slee P.H., van de Ven J., van Gorp J.M., Elbers J.R., Schipper M.E., Blijham G.H., and Thijssen J.H. Aromatase and COX-2 expression in human breast cancers. J. Steroid Biochem. Mol. Biol. 79 (2001) 41-47
2. Smith I.E., and Dowsett M. Aromatase inhibitors in breast cancer. N. Engl. J. Med. 348 (2003) 2431-2442
3. Chang J., Powles T.J., Allred D.C., Ashley S.E., Makris A., Gregory R.K., Osborne C.K., and Dowsett M. Prediction of clinical outcome from primary tamoxifen by expression of biologic markers in breast cancer patients. Clin. Cancer Res. 6 (2000) 616-621
4. Clark G.M., McGuire W.L., Hubay C.A., Pearson O.H., and Marshall J.S. Progesterone receptors as a prognostic factor in Stage II breast cancer. N. Engl. J. Med. 309 (1983) 1343-1347
5. Horwitz K.B., Koseki Y., and McGuire W.L. Estrogen control of progesterone receptor in human breast cancer: role of estradiol and antiestrogen. Endocrinology 103 (1978) 1742-1751
6. Fournet-Dulguerov N., MacLusky N.J., Leranth C.Z., Todd R., Mendelson C.R., Simpson E.R., and Naftolin F. Immunohistochemical localization of aromatase cytochrome P-450 and estradiol dehydrogenase in the syncytiotrophoblast of the human placenta. J. Clin. Endocrinol. Metab. 65 (1987) 757-764
7. Steinkampf M.P., Mendelson C.R., and Simpson E.R. Regulation by follicle-stimulating hormone of the synthesis of aromatase cytochrome P-450 in human granulosa cells. Mol. Endocrinol. 1 (1987) 465-471
8. Krasnow J.S., Hickey G.J., and Richards J.S. Regulation of aromatase mRNA and estradiol biosynthesis in rat ovarian granulosa and luteal cells by prolactin. Mol. Endocrinol. 4 (1990) 12-13
9. Levallet J., Bilinska B., Mittre H., Genissel C., Fresnel J., and Carreau S. Expression and immunolocalization of functional cytochrome P450 aromatase in mature rat testicular cells. Biol. Reprod. 58 (1998) 919-926
10. Carreau S. Germ cells: a new source of estrogens in the male gonad. Mol. Cell. Endocrinol. 178 (2001) 65-72
11. Lanzino M., Catalano S., Genissel C., Ando S., Carreau S., Hamra K., and McPhaul M.J. Aromatase messenger RNA is derived from the proximal promoter of the aromatase gene in Leydig, Sertoli, and germ cells of the rat testis. Biol. Reprod. 64 (2001) 1439-1443
12. Roselli C.E., Abdelgadir S.E., Ronnekleiv O.K., and Klosterman S.A. Anatomic distribution and regulation of aromatase gene expression in the rat brain. Biol. Reprod. 58 (1998) 79-87
13. Simpson E.R., Zhao Y., Agarwal V.R., Michael M.D., Bulun S.E., Hinshelwood M.M., Graham-Lorence S., Sun T., Fisher C.R., Qin K., and Mendelson C.R. Aromatase expression in health and disease. Recent Prog. Horm. Res. 52 (1997) 185-213
14. Means G.D., Mahendroo M.S., Corbin C.J., Mathis J.M., Powell F.E., Mendelson C.R., and Simpson E.R. Structural analysis of the gene encoding human aromatase cytochrome P-450, the enzyme responsible for estrogen biosynthesis. J. Biol. Chem. 264 (1989) 19385-19391
15. Kamat A., Hinshelwood M.M., Murry B.A., and Mendelson C.R. Mechanisms in tissue-specific regulation of estrogen biosynthesis in humans. Trends Endocrinol. Metab. 13 (2002) 122-128
16. Mahendroo M.S., Mendelson C.R., and Simpson E.R. Tissue-specific and hormonally controlled alternative promoters regulate aromatase cytochrome P450 gene expression in human adipose tissue. J. Biol. Chem. 268 (1993) 19463-19470
17. Zhou C., Zhou D., Esteban J., Murai J., Siiteri P.K., Wilczynski S., and Chen S. Aromatase gene expression and its exon I usage in human breast tumors. Detection of aromatase messenger RNA by reverse transcription-polymerase chain reaction. J. Steroid Biochem. Mol. Biol. 59 (1996) 163-171
18. Sasano H., Takashashi K., Satoh F., Nagura H., and Harada N. Aromatase in the human central nervous system. Clin. Endocrinol. (Oxf.) 48 (1998) 325-329
19. Means G.D., Kilgore M.W., Mahendroo M.S., Mendelson C.R., and Simpson E.R. Tissue-specific promoters regulate aromatase cytochrome P450 gene expression in human ovary and fetal tissues. Mol. Endocrinol. 5 (1991) 2005-2013
20. 2 via cyclic AMP, leading to activation of promoter II of the CYP19 (aromatase) gene. Endocrinology 137 (1996) 5739-5742
21. Harada N., and Honda S. Molecular analysis of aberrant expression of aromatase in breast cancer tissues. Breast Cancer Res. Treat. 49 Suppl. 1 (1998) S15-S21
22. Michael M.D., Michael L.F., and Simpson E.R. A CRE-like sequence that binds CREB and contributes to cAMP-dependent regulation of the proximal promoter of the human aromatase P450 (CYP19) gene. Mol. Cell. Endocrinol. 134 (1997) 147-156
23. Fitzpatrick S.L., and Richards J.S. Cis-Acting elements of the rat aromatase promoter required for cyclic adenosine 3′,5′-monophosphate induction in ovarian granulosa cells and constitutive expression in R2C Leydig cells. Mol. Endocrinol. 7 (1993) 341-354
24. Fitzpatrick S.L., and Richards J.S. Identification of a cyclic adenosine 3′,5′-monophosphate-response element in the rat aromatase promoter that is required for transcriptional activation in rat granulosa cells and R2C Leydig cells. Mol. Endocrinol. 8 (1994) 1309-1319
25. Michael M.D., Kilgore M.W., Morohashi K., and Simpson E.R. Ad4BP/SF-1 regulates cyclic AMP-induced transcription from the proximal promoter (PII) of the human aromatase P450 (CYP19) gene in the ovary. J. Biol. Chem. 270 (1995) 13561-13566
26. Hinshelwood M.M., Repa J.J., Shelton J.M., Richardson J.A., Mangelsdorf D.J., and Mendelson C.R. Expression of LRH-1 and SF-1 in the mouse ovary: localization in different cell types correlates with differing function. Mol. Cell. Endocrinol. 207 (2003) 39-45
27. Falender A.E., Lanz R., Malenfant D., Belanger L., and Richards J.S. Differential expression of steroidogenic factor-1 and FTF/LRH-1 in the rodent ovary. Endocrinology 144 (2003) 3598-3610
28. Liu D.L., Liu W.Z., Li Q.L., Wang H.M., Qian D., Treuter E., and Zhu C. Expression and functional analysis of liver receptor homologue 1 as a potential steroidogenic factor in rat ovary. Biol. Reprod. 69 (2003) 508-517
29. Bouchard M.F., Taniguchi H., and Viger R.S. Protein kinase A-dependent synergism between GATA factors and the nuclear receptor, liver receptor homolog-1, regulates human aromatase (CYP19) PII promoter activity in breast cancer cells. Endocrinology 146 (2005) 4905-4916
30. Tremblay J.J., and Viger R.S. GATA factors differentially activate multiple gonadal promoters through conserved GATA regulatory elements. Endocrinology 142 (2001) 977-986
31. Brueggemeier R.W., Richards J.A., and Petrel T.A. Aromatase and cyclooxygenases: enzymes in breast cancer. J. Steroid Biochem. Mol. Biol. 86 (2003) 501-507
32. Evans C.T., Corbin C.J., Saunders C.T., Merrill J.C., Simpson E.R., and Mendelson C.R. Regulation of estrogen biosynthesis in human adipose stromal cells. Effects of dibutyryl cyclic AMP, epidermal growth factor, and phorbol esters on the synthesis of aromatase cytochrome P-450. J. Biol. Chem. 262 (1987) 6914-6920
33. Mendelson C.R., Corbin C.J., Smith M.E., Smith J., and Simpson E.R. Growth factors suppress and phorbol esters potentiate the action of dibutyryl adenosine 3′,5′-monophosphate to stimulate aromatase activity of human adipose stromal cells. Endocrinology 118 (1986) 968-973
34. Bouchard M.F., Taniguchi H., and Viger R.S. Protein kinase A-dependent synergism between GATA factors and the nuclear receptor, liver receptor homolog-1, regulates human aromatase (CYP19) PII promoter activity in breast cancer cells. Endocrinology 146 (2005) 4905-4916
35. 2, liver receptor homologue-1, and aromatase in breast cancer. Cancer Res. 65 (2005) 657-663
36. Botrugno O.A., Fayard E., Annicotte J.S., Haby C., Brennan T., Wendling O., Tanaka T., Kodama T., Thomas W., Auwerx J., and Schoonjans K. Synergy between LRH-1 and β-catenin induces G1 cyclin-mediated cell proliferation. Mol. Cell 15 (2004) 499-509
37. Yang C., Zhou D., and Chen S. Modulation of aromatase expression in the breast tissue by ERRα-1 orphan receptor. Cancer Res. 58 (1998) 5695-5700
38. Suzuki T., Miki Y., Moriya T., Shimada N., Ishida T., Hirakawa H., Ohuchi N., and Sasano H. Estrogen-related receptor α in human breast carcinoma as a potent prognostic factor. Cancer Res. 64 (2004) 4670-4676
39. Ariazi E.A., Clark G.M., and Mertz J.E. Estrogen-related receptor α and estrogen-related receptor γ associate with unfavorable and favorable biomarkers, respectively, in human breast cancer. Cancer Res. 62 (2002) 6510-6518
40. Ristimaki A., Sivula A., Lundin J., Lundin M., Salminen T., Haglund C., Joensuu H., and Isola J. Prognostic significance of elevated cyclooxygenase-2 expression in breast cancer. Cancer Res. 62 (2002) 632-635
41. 2. Oncogene 23 (2004) 1631-1635
42. Cotterchio M., Kreiger N., Sloan M., and Steingart A. Nonsteroidal anti-inflammatory drug use and breast cancer risk. Cancer Epidemiol. Biomarkers Prev. 10 (2001) 1213-1217
43. Diaz-Cruz E.S., Shapiro C.L., and Brueggemeier R.W. Cyclooxygenase inhibitors suppress aromatase expression and activity in breast cancer cells. J. Clin. Endocrinol. Metab. 90 (2005) 2563-2570
44. Baldwin A.S.J. The NF-κB and IκB proteins: new discoveries and insights. Annu. Rev. Immunol. 14 (1996) 649-683
45. Cao Y., and Karin M. NF-κB in mammary gland development and breast cancer. J. Mammary Gland Biol. Neoplasia 8 (2003) 215-223
46. Biswas D.K., Dai S.C., Cruz A., Weiser B., Graner E., and Pardee A.B. The nuclear factor κB (NF-κB): a potential therapeutic target for estrogen receptor negative breast cancers. Proc. Natl. Acad. Sci. U.S.A. 98 (2001) 10386-10391
47. Zhou Y., Eppenberger-Castori S., Marx C., Yau C., Scott G.K., Eppenberger U., and Benz C.C. Activation of nuclear factor-κB (NF-κB) identifies a high-risk subset of hormone-dependent breast cancers. Int. J. Biochem. Cell Biol. 37 (2005) 1130-1144
48. Demicco E.G., Kavanagh K.T., Romieu-Mourez R., Wang X., Shin S.R., Landesman-Bollag E., Seldin D.C., and Sonenshein G.E. RelB/p52 NF-κB complexes rescue an early delay in mammary gland development in transgenic mice with targeted superrepressor IκB-α expression and promote carcinogenesis of the mammary gland. Mol. Cell. Biol. 25 (2005) 10136-10147
49. Song R.X., Barnes C.J., Zhang Z., Bao Y., Kumar R., and Santen R.J. The role of Shc and insulin-like growth factor 1 receptor in mediating the translocation of estrogen receptor α to the plasma membrane. Proc. Natl. Acad. Sci. U.S.A. 101 (2004) 2076-2081
50. Wu R.C., Qin J., Yi P., Wong J., Tsai S.Y., Tsai M.J., and O'Malley B.W. Selective phosphorylations of the SRC-3/AIB1 coactivator integrate genomic responses to multiple cellular signaling pathways. Mol. Cell 15 (2004) 937-949
51. Osborne C.K., Bardou V., Hopp T.A., Chamness G.C., Hilsenbeck S.G., Fuqua S.A., Wong J., Allred D.C., Clark G.M., and Schiff R. Role of the estrogen receptor coactivator AIB1 (SRC-3) and HER-2/neu in tamoxifen resistance in breast cancer. J. Natl. Cancer Inst. 95 (2003) 353-361
52. Wu R.C., Qin J., Hashimoto Y., Wong J., Xu J., Tsai S.Y., Tsai M.J., and O'Malley B.W. Regulation of SRC-3 (pCIP/ACTR/AIB-1/RAC-3/TRAM-1) coactivator activity by IκB kinase. Mol. Cell. Biol. 22 (2002) 3549-3561
53. Osborne C.K., Yochmowitz M.G., Knight III W.A., and McGuire W.L. The value of estrogen and progesterone receptors in the treatment of breast cancer. Cancer 46 (1980) 2884-2888
54. Ravdin P.M., Green S., Dorr T.M., McGuire W.L., Fabian C., Pugh R.P., Carter R.D., Rivkin S.E., Borst J.R., and Belt R.J. Prognostic significance of progesterone receptor levels in estrogen receptor-positive patients with metastatic breast cancer treated with tamoxifen: results of a prospective Southwest Oncology Group study. J. Clin. Oncol. 10 (1992) 1284-1291
55. Bardou V.J., Arpino G., Elledge R.M., Osborne C.K., and Clark G.M. Progesterone receptor status significantly improves outcome prediction over estrogen receptor status alone for adjuvant endocrine therapy in two large breast cancer databases. J. Clin. Oncol. 21 (2003) 1973-1979
56. Slamon D.J., Clark G.M., Wong S.G., Levin W.J., Ullrich A., and McGuire W.L. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235 (1987) 177-182
57. Tandon A.K., Clark G.M., Chamness G.C., Ullrich A., and McGuire W.L. HER-2/neu oncogene protein and prognosis in breast cancer. J. Clin. Oncol. 7 (1989) 1120-1128
58. Lebeau A., Unholzer A., Amann G., Kronawitter M., Bauerfeind I., Sendelhofert A., Iff A., and Lohrs U. EGFR, HER-2/neu, cyclin D1, p21 and p53 in correlation to cell proliferation and steroid hormone receptor status in ductal carcinoma in situ of the breast. Breast Cancer Res. Treat. 79 (2003) 187-198
59. Arpino G., Weiss H., Lee A.V., Schiff R., De Placido S., Osborne C.K., and Elledge R.M. Estrogen receptor-positive, progesterone receptor-negative breast cancer: association with growth factor receptor expression and tamoxifen resistance. J. Natl. Cancer Inst. 97 (2005) 1254-1261
60. Horwitz K.B., Francis M.D., and Wei L.L. Hormone-dependent covalent modification and processing of human progesterone receptors in the nucleus. DNA 4 (1985) 451-460
61. Wei L.L., Gonzalez-Aller C., Wood W.M., Miller L.A., and Horwitz K.B. 5′-Heterogeneity in human progesterone receptor transcripts predicts a new amino-terminal truncated "C"-receptor and unique A-receptor messages. Mol. Endocrinol. 4 (1990) 1833-1840
62. Vegeto E., Shahbaz M.M., Wen D.X., Goldman M.E., O'Malley B.W., and McDonnell D.P. Human progesterone receptor A form is a cell- and promoter-specific repressor of human progesterone receptor B function. Mol. Endocrinol. 7 (1993) 1244-1255
63. Chalbos D., and Galtier F. Differential effect of forms A and B of human progesterone receptor on estradiol-dependent transcription. J. Biol. Chem. 269 (1994) 23007-23012
64. Clarke R.B., Anderson E., and Howell A. Steroid receptors in human breast cancer. Trends Endocrinol. Metab. 15 (2004) 316-323
65. Mote P.A., Bartow S., Tran N., and Clarke C.L. Loss of co-ordinate expression of progesterone receptors A and B is an early event in breast carcinogenesis. Breast Cancer Res. Treat. 72 (2002) 163-172
66. Lydon J.P., DeMayo F.J., Funk C.R., Mani S.K., Hughes A.R., Montgomery Jr. C.A., Shyamala G., Conneely O.M., and O'Malley B.W. Mice lacking progesterone receptor exhibit pleiotropic reproductive abnormalities. Genes Dev. 9 (1995) 2266-2278
67. Mulac-Jericevic B., Mullinax R.A., DeMayo F.J., Lydon J.P., and Conneely O.M. Subgroup of reproductive functions of progesterone mediated by progesterone receptor-B isoform. Science 289 (2000) 1751-1754
68. Mulac-Jericevic B., Lydon J.P., DeMayo F.J., and Conneely O.M. Defective mammary gland morphogenesis in mice lacking the progesterone receptor B isoform. Proc. Natl. Acad. Sci. U.S.A. 100 (2003) 9744-9749
69. Condon J.C., Hardy D.B., Kovaric K., and Mendelson C.R. Upregulation of the progesterone receptor (PR)-C isoform in laboring myometrium by activation of NF-κB may contribute to the onset of labor through inhibition of PR function. Mol. Endocrinol. 20 (2006) 764-775
70. Wei L.L., Hawkins P., Baker C., Norris B., Sheridan P.L., and Quinn P.G. An amino-terminal truncated progesterone receptor isoform, PRc, enhances progestin-induced transcriptional activity. Mol. Endocrinol. 10 (1996) 1379-1387
71. Wei L.L., Norris B.M., and Baker C.J. An N-terminally truncated third progesterone receptor protein, PR(C), forms heterodimers with PR(B) but interferes in PR(B)-DNA binding. J. Steroid Biochem. Mol. Biol. 62 (1997) 287-297
72. D.B. Hardy, B.A. Janowski, D.R. Corey, C.R. Mendelson, Progesterone receptor (PR) plays a major anti-inflammatory role in human myometrial cells by antagonism of NF-κB activation of cyclooxygenase 2 (COX-2) expression, Mol. Endocrinol., 2006, in press.
73. Loudon J.A., Elliott C.L., Hills F., and Bennett P.R. Progesterone represses interleukin-8 and cyclo-oxygenase-2 in human lower segment fibroblast cells and amnion epithelial cells. Biol. Reprod. 69 (2003) 331-337
74. Hardy D.B., MacDonald E., Smith M., and Mendelson C.R. Developmental regulation of the eicosanoid pathway mediates the induction of surfactant protein-A (SP-A) expression in the fetal lung. J. Soc. Gynecol. Invest. 13 Suppl. 2 (2006) 242A
75. Tazawa R., Xu X.M., Wu K.K., and Wang L.H. Characterization of the genomic structure, chromosomal location and promoter of human prostaglandin H synthase-2 gene. Biochem. Biophys. Res. Commun. 203 (1994) 190-199
76. Newton R., Kuitert L.M., Bergmann M., Adcock I.M., and Barnes P.J. Evidence for involvement of NF-κB in the transcriptional control of COX-2 gene expression by IL-1β. Biochem. Biophys. Res. Commun. 237 (1997) 28-32
77. Soloff M.S., Cook Jr. D.L., Jeng Y.J., and Anderson G.D. In situ analysis of interleukin-1-induced transcription of COX-2 and IL-8 in cultured human myometrial cells. Endocrinology 145 (2004) 1248-1254
78. Kalkhoven E., Wissink S., van der Saag P.T., and van der Burg B. Negative interaction between the RelA(p65) subunit of NF-κB and the progesterone receptor. J. Biol. Chem. 271 (1996) 6217-6224
79. Allport V.C., Pieber D., Slater D.M., Newton R., White J.O., and Bennett P.R. Human labour is associated with nuclear factor-κB activity which mediates cyclo-oxygenase-2 expression and is involved with the 'functional progesterone withdrawal'. Mol. Hum. Reprod. 7 (2001) 581-586
80. Dumont A., Hehner S.P., Schmitz M.L., Gustafsson J.A., Liden J., Okret S., van der Saag P.T., Wissink S., van der Burg B., Herrlich P., Haegeman G., De Bosscher K., and Fiers W. Cross-talk between steroids and NF-κB: what language?. Trends Biochem. Sci. 23 (1998) 233-235
81. Wissink S., van Heerde E.C., Schmitz M.L., Kalkhoven E., van der Burg B., Baeuerle P.A., and van der Saag P.T. Distinct domains of the RelA NF-κB subunit are required for negative cross-talk and direct interaction with the glucocorticoid receptor. J. Biol. Chem. 272 (1997) 22278-22284
82. McKay L.I., and Cidlowski J.A. CBP (CREB binding protein) integrates NF-κB (nuclear factor-κB) and glucocorticoid receptor physical interactions and antagonism. Mol. Endocrinol. 14 (2000) 1222-1234
83. Sheppard K.A., Phelps K.M., Williams A.J., Thanos D., Glass C.K., Rosenfeld M.G., Gerritsen M.E., and Collins T. Nuclear integration of glucocorticoid receptor and nuclear factor-κB signaling by CREB-binding protein and steroid receptor coactivator-1. J. Biol. Chem. 273 (1998) 29291-29294
84. Scheinman R.I., Cogswell P.C., Lofquist A.K., and Baldwin A.S. Role of transcriptional activation of IκBα in mediation of immunosuppression by glucocorticoids. Science 270 (1995) 283-286
85. Miller L., and Hunt J.S. Regulation of TNF-α production in activated mouse macrophages by progesterone. J. Immunol. 160 (1998) 5098-5104
86. Deroo B.J., and Archer T.K. Differential activation of the IκBα and mouse mammary tumor virus promoters by progesterone and glucocorticoid receptors. J. Steroid Biochem. Mol. Biol. 81 (2002) 309-317